Login to Your Account



FDA Grants SPA for Puma's PB272 Breast Cancer Trial

By Catherine Shaffer
Staff Writer

Thursday, February 21, 2013
Puma Biotechnology Inc. said its Phase III trial of PB272 (neratinib) will be conducted under a special protocol assessment from the FDA, providing specific guidance for design, endpoints and statistical analysis in the trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription